Ulcerative colitis (UC) specifically affects the colon and rectum through multifactorial
mechanisms associated with genetic alterations, environmental factors, microbiota, and …

Background Inflammatory bowel diseases [IBD]―ulcerative colitis and Crohn's disease―are
commonly treated with biologic drugs. However, only approximately two-thirds of patients …

The advent of anti-TNF agents as the first approved targeted therapy in the treatment of
inflammatory bowel disease (IBD) patients has made a major impact on our existing …

Objective Anti-tumour necrosis factor (TNF) antibodies are successfully used for treatment of
Crohn's disease. Nevertheless, approximately 40% of patients display failure to anti-TNF …

Primary nonresponse and primary nonremission are important limitations of tumor necrosis
factor (TNF) antagonists, occurring in 10% to 40% and 50% to 80% of patients with …

Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat
inflammatory bowel disease (IBD) in the clinical practice. In this review, the principal …

Spondyloarthritis (SpA) encompasses a heterogeneous group of chronic inflammatory
diseases that can affect both axial and peripheral joints, tendons and entheses. Among the …

Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are
characterized by chronic idiopathic inflammation of gastrointestinal tract. Although the …

The treatment of IBD with anti-TNF agents has substantially evolved since their first
introduction more than a decade ago. The robust efficacy witnessed in many patients has …

The use of biologic agents, particularly anti-tumor necrosis factor (TNF)-α, has revolutionized
the treatment of inflammatory bowel diseases (IBD), modifying their natural history. Several …